ReviewMicroorganisms2025
A Review of the Epidemiology of Lassa Fever in Nigeria.
Review in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Strengthening diagnostic capacity for viral hemorrhagic fevers in Forest Guinea: advances in Lassa fever case detection.Npj viruses · 2026Article
- In silico prioritization and cheminformatics identify structurally diverse small-molecule inhibitors of Lassa virus glycoprotein-mediated membrane fusion.SLAS discovery : advancing life sciences R & D · 2026Article
- Temporal dynamics, climate associations, and surveillance performance of Lassa fever in Nigeria, 2020-2025: a national longitudinal analysis.Osong public health and research perspectives · 2026Article
- Emerging Mammarenaviruses in Wildlife: Expanding Host Range and Implications.Animals : an open access journal from MDPI · 2026Review
- Design of a global population-covering multi-epitope mRNA vaccine against Lassa virus using immunoinformatics.Scientific reports · 2026Article
- Development of a Conditional Replication System Using a Lassa Virus Glycoprotein Complex-Encoding Retroviral Vector for Isolating Resistant Variants to Inhibitors in BSL-2.International journal of molecular sciences · 2026Article
- Research Output and Global Trends in Lassa Fever: A 50-Year Bibliometric Analysis (1975-2025).BioMed research international · 2026Review
- Modelling the effects of climate and human factor on Lassa fever distribution in Ondo State Nigeria.International journal of biometeorology · 2025Article
- The resurgence of Lassa fever in Nigeria: economic impact, challenges, and strategic public health interventions.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lassa fever, a viral hemorrhagic illness that first came into the limelight as a clinical entity in 1969 when it was discovered in Northern Nigeria, is now found in other West African countries such as Sierra Leone, Liberia, Guinea, Togo, and the Benin Republic. Over the years, the disease, which is primarily transmitted from contact with infected mastomys rodents to humans, has the capability of secondary human-to-human transmission with significant morbidity and mortality, especially in healthcare settings. The disease is typically characterized by seasonal outbreaks, which peak during the dry season months of December to March. Lassa fever significantly impacts public health and the socioeconomic life of people in affected communities. In Nigeria, the Integrated Disease Surveillance and Response Strategy (IDSR), along with other medical countermeasures, have been employed to curtail the impact of the disease in endemic regions of Nigeria and other West Africa countries. The one-health approach to combat the disease is a promising strategy. This, along with the hope of a safe and effective vaccine, is a ray of hope on the horizon for public health authorities in Nigeria and other West African countries that the battle against Lassa fever might indeed end sooner than later.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.